Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

By LabMedica International staff writers
Posted on 27 Jul 2026

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. More...

Type I interferons are central to host defense, yet their failure in critical illness has been difficult to explain. Clarifying this mechanism could guide risk assessment for viral infections that continue to burden health systems. New findings demonstrate how pre-existing immune factors can disable type I interferon activity in people who developed severe COVID-19.

At the University of Sharjah, investigators and international collaborators found that an affinity-matured autoimmune B‑cell response generates antibodies capable of neutralizing type I interferons. Under normal conditions, these cytokines alert neighboring cells and initiate antiviral programs; however, the study shows that in a subset of patients, the antibodies target interferon‑α and interferon‑ω and block their function. The work identifies three principal B‑cell epitopes spanning all major regions of type I interferons, explaining the breadth of neutralization.

The team combined patient‑derived monoclonal antibodies with X‑ray crystallography and AlphaFold3‑based structural analyses to map antibody–interferon interactions in detail. Extensive somatic hypermutation and evidence of prolonged affinity maturation were observed, indicating a mature, organized autoimmune response rather than a transient byproduct of severe infection. Researchers examined hundreds of antibodies, revealing how this response can exist silently prior to viral exposure and then undermine innate defenses at infection onset.

According to the authors, the findings help explain why some individuals progressed to life‑threatening disease during SARS‑CoV‑2 infection and may be relevant to other respiratory viruses, including seasonal influenza. The study is global in scope, with contributors from universities and research institutes across France, Switzerland, Canada, Spain, Belgium, Saudi Arabia, Sweden, Denmark, Italy, the U.S., Estonia, and the United Arab Emirates. The work was published in Cell.

“The researchers found that these patients had a large and diverse population of B cells specifically programmed to recognize interferons,” said Rabih Halwani, professor of immunology at the University of Sharjah. “Importantly, this abnormal immune response was detectable before the patients developed life-threatening viral disease, suggesting that it was not simply a consequence of severe infection but rather a pre-existing defect that may have contributed to the patients' vulnerability.”

Related Links
University of Sharjah


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.